Dr Bischof received his PhD from The University of Melbourne, and held research positions at the University of Melbourne, Royal Melbourne Hospital and Monash University prior to joining The Ritchie Centre at the Hudson Institute in 2015.
With both academic and commercial research interests, Dr Bischof has held leadership and advisory positions at various levels in the Biotech Industry field. He is a founding member and the Chief Scientific Officer for Allergenix Pty Ltd, an Australian biotechnology company focussed on pulmonary disease and drug delivery, and inventor on three patents in the allergy and asthma field. He also currently holds an Adjunct appointment at the Monash Institute of Pharmaceutical Sciences.
Dr Bischof has significant research expertise in tissue inflammation and cytokine research in the biomedical and veterinary fields, encompassing studies on the role of immune cells in inflammation, health and disease, and the development and application of animal models for biomedical research. His work has attracted broad academic and industry funding from organisations including the National Health and Medical Research Council, the Australian Research Council and The Bill and Melinda Gates Foundation.
Dr Bischof’s main research focus is on the pathophysiology of airway disease and translational studies on pulmonary therapeutics using large animal models.